Phase 2 N=18 Targeting Oxidative Stress in Chronic Beryllium Disease
Chronic Beryllium Disease
Primary: Change in Beryllium Lymphocyte Proliferation Responses (BeLPT) From Baseline to Week 6 — 48.61; 9.33; 22.07; 3.8 Stimulation index
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=17 Characterization of Tissue-Specific Immune Responses to Bronchoscopic Instillation of Mycobacterial Antigens Into the Human Lung
Healthy · Latent Tuberculosis Infection (LTBI)
Primary: Median Difference in CD4 Cell Response to Intrabronchial Instillation of Tuberculin Purified Protein Derivative (PPD) — 5.26; 0.725; 29.9; 2.92 % Antigen Specific T…
Phase 2 N=48 Effect of BIBW 2948 BS in COPD
Pulmonary Disease, Chronic Obstructive · Bronchitis, Chronic
Primary: Change From Baseline in Volume of Mucin Per Surface Area of Basal Lamina — 2.565; 1.180 micrometer^3/micrometer^2 — p=0.5305
Phase 2 N=16 Inhaled Beclomethasone After Community-Acquired Respiratory Viral Infection in Lung Transplant Recipients
Lung Transplant Infection
Primary: Number of Participants Free From New or Progressive Chronic Lung Allograft Dysfunction — 2; 4 Participants
N/A N=256 Analysis of BPD in Premature Infants With Typical Imaging Changes
Bronchopulmonary Dysplasia
Primary: Mortality — 17; 7 Participants
Phase 2 N=17 Belimumab Treatment of Emphysema Patients With Anti-GRP78 Autoantibodies
Chronic Obstructive Pulmonary Disease · Emphysema
Primary: Percent Change of Circulating Anti-GRP78 IgG Levels — -17.0; -2.6 % change
Phase 3 N=48 Voriconazole For Chronic Bronchopulmonary Aspergillosis
Aspergillosis
Primary: Number of Subjects With Successful Global Outcome at 6 Months: Chronic Bronchopulmonary Aspergillosis — 13; 28 participants
N/A N=119 Early Identification of Myocardial Impairment in PBC
Primary Biliary Cholangitis · Cardiovascular Abnormalities
Primary: The Incidence of Cardiac Events — 0; 0; 0; 0 Participants — p=0.001
Phase 2 N=88 Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Respiratory Distress Syndrome in Premature Infant · Bronchopulmonary Dysplasia
Primary: Survival Without Evidence of Chronic Pulmonary Insufficiency of Prematurity (CPIP) at 12 Months Corrected Gestational Age (CGA) — 8; 2; 6; 6 Number of events
Phase 2 N=7 Extension Study (Extended Access) of Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans
Bronchiolitis Obliterans · Constructive Bronchiolitis · Graft Versus Host Disease
Primary: Improvement in Lung Function - Increase in FEV1 — 0 Participants
Phase 3 N=12 Betaine and Peroxisome Biogenesis Disorders
Peroxisome Biogenesis Disorders
Primary: Peroxisome Biochemical Functions as Measured by Plasma Very Long Chain Fatty Acid — 0.180; 0.188 ratio
N/A N=104 Assessment of Safety of Air Travel in Patients With Birt-Hogg-Dube Syndrome
Birt-Hogg-Dube Syndrome
Primary: Number of Patients With Birt-Hogg-Dube Syndrome Who Experienced Spontaneous Pneumothorax During or Within 24 Hours Following Air Travel — 8 Participants
Phase 1 N=10 Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation
Graft Vs Host Disease · Graft-versus-host-disease
Primary: Safety and Tolerability of Belimumab as Prophylaxis of Chronic GvHD in Subjects Following alloHCT as Measured by Number of Participants Who Experience Each Adverse Event…
Phase 1 N=12 Aerosol BCG Challenge Study in Historically BCG-vaccinated Volunteers
Tuberculosis
Primary: To Quantify BCG Recoverable From Bronchial Sample — 0; 0; 0; 0 Volunteers with detectable BCG
Phase 2 N=122 Clinical Evaluation of Metal Panel Allergens: Dose Response Study
Dermatitis, Eczematous
Primary: Number of Participants With Patch Test Responses — 0; 105; 16; 0 Participants
N/A N=50 BPD Saturation TARgeting
Bronchopulmonary Dysplasia · Chronic Lung Disease of Prematurity · Chronic Lung Disease
Primary: Intermittent Hypoxemia (IH) Events Per 8 Hours of Monitoring Time — 2.2; 1.2 IH events per 8 hours of monitoring time
Early Phase 1 N=8 Benzo[a]Pyrene Ultralow Dose-Response Study
Environmental Exposure
Primary: Peak Plasma Concentration Cmax — 2.51; 5.68; 13.8; 8.99 fg [14C]-BaP/mL plasma
N/A N=20 Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis
Light Chain Deposition Disease (LCDD or MIDD) · Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD) · Monoclonal Immunoglobulin Deposition Disease (MIDD)
Primary: Percentage of Participants Experiencing Progression Free Survival at 12 Months — 84 percentage of patients
N/A N=187 GER Poses a Potential Risk for Late Complications of BPD
Gastroesophageal Reflux · Bronchopulmonary Dysplasia
Primary: the Late Complications of BPD Infants — 57; 45; 30; 4 Participants
Phase 2 N=56 Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study
Contact Dermatitis
Primary: Number of Participants Who Exhibit Positive Responses to Each Allergen Concentration — 4; 0; 0; 2 Participants
Phase 2 N=30 Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
Cystic Fibrosis · Bronchiectasis Adult · Non-Tuberculous Mycobacteria
Primary: BCG Uptake — 48.06; 0.84; 35.97 spot forming units
Phase 3 N=122 GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants
Phase 4 N=197 Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Hepatitis B, Chronic
Primary: Incidence Rate of Newly Diagnosed Hepatocellular Carcinoma (HCC) at Week 240 — 6.045 Events per person-year
N/A N=252 Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
COPD
Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001
N/A N=270 Comparison of Classification Standards of Bronchopulmonary Dysplasia (BPD) in Premature Infants
Bronchopulmonary Dysplasia
Primary: Respiratory Adverse Outcomes — 27; 60 Participants
Phase 1 N=16 Inhaled Tobramycin in BPD
Bronchopulmonary Dysplasia
Primary: Elevated Serum Tobramycin Trough or Creatinine or Severe Adverse Event — 0; 0; 0; 1 Participants
Phase 3 N=616 BUILD 3: Bosentan Use in Interstitial Lung Disease
Idiopathic Pulmonary Fibrosis
Primary: Time to Occurrence of Disease Worsening or Death up to End of Study. — 10; 18; 22; 40 participants with event — p=0.2110
Phase 1 N=10 Tobramycin Inhalation Powder (TIP) in Cystic Fibrosis Patients Infected With Burkholderia Cepacia Complex
Cystic Fibrosis · Burkholderia Cepacia Infection
Primary: The Change in Sputum Density of BCC in Colony Forming Units (CFUs)/ml From Day 0 to Day 28 of TIP Treatment. — -1.4 CFU/ml log10
Phase 4 N=17 Bronchodilator Responsiveness in Obliterative Bronchiolitis
Obliterative Bronchiolitis
Primary: Per Cent Change of Forced Expiratory Volume in 1 Second (FEV1) After Bronchodilators — 14; 7 per cent positive change
Phase 2 N=108 A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)
Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular · Lymphoma, Mantle-Cell
Primary: Number of Patients With a Clinically Meaningful Reduction in Lung Toxicity, Defined as a Reduction of the Diffusion Capacity of the Lung for Carbon Monoxide (DLCO) by at…